Saponin SC-2 from Solanum chrysotrichum showed antifungal activity, demonstrated in vitro, which inhibited the growth of dermatophytes, and in vivo, to be effective in the treatment against tinea pedis and pityriasis capitis. Fungistatic and fungicidal activity of saponin SC-2 on Candida albicans and other Candida species, fluconazole and ketoconazole resistaent strains was demostrated. SC-2-associated ultrastructural alterations in several Candida species were observed. An exploratory clinical, randomized, double-blind, and controlled ketoconazole study of ketoconazole was conducted with the aim of assessing the effectiveness and tolerability of an herbal medicinal product containing SC-2, on women with Vulvovaginal candidiasis (VVC). The results exhibited a percentage of therapeutic clinical effectiveness similar to that of ketoconazole (X 2 , p ≥0.30), but obtained a smaller percentage of mycological effectiveness, and 100% tolerability. In conclusion, saponin SC-2 possesses fungicidale and fungistatic activity on Candida albicans and other multi resistant Candida species, causes morphological changes and fungal death, and it is an alternative therapy for the treatment of VVC.
Introduction
According to numbers of the World Health Organization (WHO), up to 70% of the world population, especially, in some Asian and African countries, depends on traditional medicine for their primary health care. This is in part due to limited access to synthetic drugs for logistic and economic reasons, but also is because of cultural reasons: indigenous persons may also make a positive choice for traditional medicine because they believe in its healing powers. Thus, the WHO has an active policy of integrating traditional medicine into local health care systems. The use of plant preparations can be supported if these are safe and if their activity can be scientifically confirmed. This implies the need for quality control and standardization (Caballero and Gupta, 2011; Xu, et al., 2011) .
Medicinal plants remain an endless source of traditional herbal medicine and the approach has led to the discovery of numerous pharmacologically active molecules and drug leads for humans. Evidence of the biomedical potential of herbal drugs employed worldwide in traditional medicine is continually being reported. Biological activities, include those of being antioxidant, antihypertensive agents, antitumor promoter, antimutagenic, cytotoxic for cancer cell lines, possessing an antiinflammatory effect, managing of Diabetes mellitus (DM), treating of cardiovascular diseases, enhancing the production of selected blood parameters, and having hepatoprotector activities, allergic asthma activities, immune response activities and immunosuppressive activities (Afifi, et al. The Solanum chrysotrichum plant species has been used in Mexican traditional medicine for the treatment of dermatological infections. Phytochemical and microbiological studies have reported isolation, structural identification, and antifungal activity in dermatophytes and in the Malassezia species of Spirostatic saponin SC-2 ( Figure 1) 
Clinical data
The most frequent symptoms of VVC comprise the following: pruritus (56%); vaginal discharge (69%); dyspareunia (25%); vulvar itching or burning (38%); vulvar swelling/edema (25%); white discharge (68%), and vulvar redness (22%). 
Candida species causes VVC
Yeast strains isolated from the vagina are C. albicans in between 85 and 95% of cases and the remainder includes other Candida species the most common of which is Candida glabrata. In many parts of the world, C. glabrata affects 10-20% of women and often causes RVVC. Other species found that caused VVC are as follows: C. parapsilosis, C. tropicalis, C. kefyr, C. lusitaniae and C. krusei. These other Candida species that caused VVC are clinically indistinguishable from those caused by C. albicans; moreover, such species are often more treatment-resistant, and clinical signs and symptoms of infection caused by C. glabrata and C. parapsilosis tend to be associated with milder, and often absent symptoms (Consaro, et al., 2004; Murina, et al., 2011; Ray et al., 2011) . A higher cumulative incidence of Candida spp. colonization is reported in some women. Blastoconidia represent the phenotypic form responsible for vaginal transmission and asymptomatic colonization of the vagina. Germinated yeasts, which have produced mycelia (hyphae), are found most commonly in symptomatic vaginitis. Sexual transmission and asymptomatic colonization of the male genitalia with Candida is four times more common in the sexual partners of infected women than in those of non-infected women (Sobel, 2007; Hoffstetter, et al., 2008; Fisher and Bradford, 2011) .
Predisposing factors
The principal predisposing factors for VVC are the following: i) therapy with antibacterial drugs, such as systemic broad spectrum antibiotics (tetracycline or amoxicillin clavulinate); these can eliminate the protective bacterial flora. Lactobacillus spp. could provide colonization resistance and prevent germination, maintaining low numbers of yeast; ii) pregnancy, a higher prevalence of vaginal colonization and symptomatic vaginitis are more often observed in pregnant women; iii) contraceptives, these increase vaginal colonization with Candida after the use of oral contraceptives with high estrogen content and in users of intrauterine contraceptive devices, contraceptive sponges, diaphragms, and condoms, with or without spermicides; iv) patients with DM; v) HIV infection, the number of women with HIV grew in the 1980s, vaginal candidiasis was also increasingly reported, and there is a tendency to isolate notably C. glabrata and Candida isolates notably with reduced sensitivity to fluconazole; vi) behavioral factors, the incidence of VVC increases in the second decade of life, corresponding to the onset of sexual activity, cultural differences affect the frequency of Candida species in some groups, women's culture and ethnicity influence their diet, hygiene, and sometimes the use of modern medicine, among other factors; vii) hypersensitivity, chemical contact, atopy, local allergy, or hypersensitivity reactions could alter the vaginal milieu and facilitate transformation from asymptomatic colonization into symptomatic vaginitis (Goswami et al., 2006; Sobel, 2007; Wei, et al., 2010; Fisher and Bradford, 2011) .
Resistance of Candida species to conventional therapy
The recommended therapy for VVC is topical vaginal treatment with imidazoles; other therapy comprises topical application of nystatin, amphotericin B, fluconazole, ketoconazole and miconazole, and oral itraconazole. Systemic therapy is recommended when the infection is severe or recurrent or if the patient has major predisposing factors (AIDS or chemotherapy for cancer). Imidazoles have a potential side effect of systemic toxicity, which has dramatically restricted the use of ketoconazole (Kaplanek, 
Microbiological studies and ultrastructural changes in fluconazole-susceptible or -resistant Candida species by SC-2
In recent years, an increase has been reported in the number of patients, principally immunocompromised, with local or systemic infections caused by Candida genus yeasts; thus, there is also an increase of cases with candidiasis resistance or multiresistance to conventional antifungals. Susceptibility or resistance profiles to fluconazole, itraconazole, ketoconazole, and amphotericin B for all strains were assessed and compared with the saponin SC-2 effect. SC-2 displayed fungistatic and fungicidal activities against all of the Candida strains assayed. Minimal fungicidal concentration (MFC) was defined as the minimal concentration at which no visible growth was observed and represents the killing of >99% of the original inocula. Growth inhibition and fungicidal activity was observed at a SC-2 concentration between 200 and 800 μg/mL (Herrera-Arellano, et al., 2007).
C. albicans was highly susceptible to SC-2 concentration, while C. glabrata (that was resistant to the drugs tested) was less susceptible to SC-2 (IC50 and MFC = 800 μg/mL). SC-2 exhibited fungistatic and fungicidal activities on fluconazole susceptible or not C. albicans and other Candida species. The difference in susceptibility of Candida strains to SC-2 can be related with the chemical composition of the fungal membrane and the cell wall, which vary for each species (Herrera-Arellano et al., 2007). Ultrastructural damages on Candida species were described by Herrera and collegues. The antifungal activity of SC-2 was shown in clinical isolates of C. albicans and, C. lusitaniae (fluconazole-susceptible strains) and in, C. glabrata and, C. krusei (fluconazole-resistant strains). Despite that C. albicans is more susceptible than other species tested in SC-2, all these showed the same alterations between 6 and 12 h postexposure by Transmission electron microscopy (TEM) (Figure 2 ). Membranes appeared disrupted and organelles such mitochondria and nucleus lost conventional morphology. Damage increase gradually, with the disappeararance of organelle organization, cytoplasm degradation and finally, cellular disintegration. Deformation, degradation and loss of cellular wall were observed as well. The changes observed were dramatically irreversible and causeed cell death at 24-48h post exposure in all strains assayed (Herrera-Arellano, et al., 2007).
Exploratory study on the clinical effectiveness of SC-2 from S. chrysotrichum
With the aim of exploring the effectiveness and tolerability of an herbal medicinal product developed from an extract of S. chrysotrichum, standardized in SC-2, in the treatment of patients with cervical or vaginal infection caused by Candida genus yeasts, we implemented a randomized, double_blind clinical trial controlled with ketoconazole (Herrera-Arellano, et al., 2009). Experimental treatment was formulated with 125 mg of the dry S. chrysotrichum extract, containing 33.72 mg of total saponins and 1.89 mg of SC-2. Control treatment contained 400 mg of ketoconazole United States Pharmacopeia (USP). Both treatments were prepared as vaginal suppositories, with de the same presentation. The inclusion factor in the study was women with clinical diagnoses of VVC wich was confirmed by mycological studies including direct examination, culture, and Candida species identification (Hoffstetter et al., 2008) . The study did not include patients with diabets, breast-feeding women, and cases with VVC complicated by parasites and/or bacteria and with local or systemic administration of anti-fungal treatment during the month prior to the study. The experimental procedure consisted of the following four evaluations: before treatment (0); at days 3-4 of treatment initiation (1); after concluding a 7-day treatment (2), and 3 weeks after concluding the treatment (3). These evaluations consisted of clinical assessment (based on the intensity of genital infection-related signs and symptoms) and mycological studies (direct examination and culture, and identification of the Candida species at baseline conditions). Seven suppositories were provided to each study participant for deep vaginal application of one suppository each night before going to bed. For mycological studies, two samples of genital discharge from cervix and vaginal wall were taken to practice direct examination, yeast isolation and identification. Direct examination was positive on observing yeasts and the pseudohyphae characteristic of Candida infection. For isolation, yeasts were grown, purified, and identified. Clinical trial evaluated the following outcomes: a) clinical effectiveness, declared when signs and symptoms attributed to VVC were totally absent; b) mycological effectiveness, achieved upon detection of a negative direct examination and culture; c) therapeutic effectiveness, when clinical and mycological improvement coincided, and d) tolerability, determined by the absence of local and systemic side effects attributed to the assigned treatment. Post-treatment effectiveness was discerned by means of clinical and mycological evaluations, conducted 3 weeks after the treatment ended. The study included 101 women (49 were in the experimental group). On average, patient age was 33 years (range, 17-54 years), clinical-condition evolution time was 9 months, number of pregnancies was two (range, 0-9 pregnancies), and number of sexual partners was 1.2 (range, 1-6 sexual partners). The majority of patients had already received some previous pharmacological treatment, used cotton clothing, and a few utilized tampons; there were no significant differences on comparing these parameters in both treatment groups (p ≥0.21). Under baseline conditions, the intensity of signs and symptoms that the patients in both groups presented was not different (p ≥0.18); a moderate clinical condition predominated. In relation to mycological studies at study initiation, there were no differences between groups (p ≥0.39), direct examination was positive in 70% of cases, the culture was positive in 91%, isolating mainly C. albicans (71.74%) followed by C. glabrata (26.08%), and in only two cases, C. tropicalis (2.17%). At day 4 of treatment initiation, only mycological effectiveness reached statistical differences favorable to the control treatment, because the fungus was eradicated in 79.07% of cases, compared with eradication in 48.78% obtained by S. chrysotrichum treatment (p = 0.004). When finalizing the 7 treatment days, at the end of the administration period, percentages of mycological and therapeutic-but not clinical-effectiveness were higher in the control group (p ≤0.01). Only one half of patients who initiated the study presented for the final evaluation, which was conducted 3 weeks after treatment conclusion. Despite this, outcomes in this study phase showed no significant differences (X 2 , p ≥0.30); the majority of patients exhibited absence of signs and symptoms related with VVC as well as negative mycological studies. It is noteworthy that in this last evaluation, the percentage of fungus eradication in the S. chrysotrichum-treated group was higher than that on conclusion of the 7-day treatment (62.86 vs. 79.17%), which indicates that this possesses a residual antifungal effect.
Conclusion
SC-2 has fungistatic and/or fungicidal activity, demonstrated by IC 50 and MCF; the mechanism is unknown by TEM, but it could possibly be analogous to that of the secondary metabolites, such as the steroidal glycoalkaloids alpha-solanine, alphachaconine, and alpha-tomatine, as well as solandidine aglycone, which interact with the cytoplasmic-membrane sterols, causing structural alterations and permeabilization, all of which lead to cell destruction. Plant glycoalkaloids can act on fungal cell membranes, which includes the following three steps: i) insertion of the membrane bilayer; ii) formation of a sterol-glycoalkaloid complex, and iii) membrane rearrangement. The final effect concludes with the formation of membrane channels with an increase in their permeability that, facilitates the escape of small cytoplasm molecules, causing membrane disruption. These cytoplasmicmembrane lesions cause irreversible damage and intracellular organelle disintegration, which inhibits the growth of the fungus, and finally, death (Herrera-Arellano, et al., 2007). Additionally, the saponins, including SC-2, possess a detergent effect that diminishes superficial tension, causing cell-wall damage and fungal-cell disintegration. Additional studies are necessary to clarify the action mechanism of SC-2.
Our clinical study shows that, when concluding the 7 treatment days of treatment and at the dose employed the S. chrysotrichum herbal medicinal product, containing 125 mg of extract with 33.72 mg of total saponins and standardized in 1.89 mg of SC-2, exhibited a percentage of therapeutic clinical effectiveness that was not different from that obtained with ketoconazole, but it did obtain a smaller percentage of mycological effectiveness, and 100% tolerability. The severe in vitro damage observed in Candida species caused by SC-2 can explain the results observed on clinical study. These results allow consideration of SC-2 as an excellent alternative for treatment of VVC. Clinical studies, with higher doses to SC-2, are necessary to increase its clinical and mycological therapeutic effectiveness in VVC (Herrera-Arellano, et al., 2007; Herrera-Arellano, et al., 2009).
